GCIAvacta's AffiDX® test can identify Omicron variant in clinical samples
The government has unquestionably done a marvellous job with vaccinations.
However one area where I'm a little less convinced, relates to its covid testing strategy. Here it encouraged many domestic UK firms to develop world-beating RLFTs, which has happened. Only then to seemingly back-track, cancel contracts (eg ) & opt instead for mostly overseas suppliers (eg Chinese or US).
Today came news that – following trials in Madrid - world beating, user friendly & highly accurate RLFT has able to correctly identify the Omicron variant in clinical samples. This is in addition to all previously identified variants of concern (Re WHO).
CEO Alastair Smith adding “We are delighted to confirm that [our] AffiDX SARS-CoV-2 antigen lateral flow test detects the Omicron variant.
We are progressing with our application to the CTDA in order to [sell] the product in the UK, as well as continuing to pursue commercial opportunities in Europe & further afield for professional-use. [On top] we continue to work with Medusa19.com to obtain the CE mark for consumer self-testing.
”Elsewhere, also watch out for the release of initial pk data wrt Phase 1 clinical trial of Prodoxorubicin/AVA6000 – expected sometime over the next month or so.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.